Why the fuck did he just NOW make this video? We've been spamming this for years (March 2020) getting called QAnon conspiracy theorists. What is Ralph Baric's connections to UNC Chapel Hill? 1986-1990 NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant Coronavirus” Filed 2002 and issued 2007 (https://patents.google.com/patent/US7279327B2/ru) The paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf 1990 Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain. (https://patents.google.com/patent/US6372224B1/) 1990s Work focused on CoV association with cardiomyopathy (see above) Early reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf 2001 National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI 2002 Asia CoV SARS outbreak 2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus. Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges Scientific Advisory Board (served through 2010). April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319 July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2 Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants: A128785, A148436, and A1053822. 2004 January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. (https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706) At this conference, the term “The New Normal” was introduced by Merck... FAUCI AND BARIC start profiting!!! SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection. National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million. November 22, 2004 University of Hong Kong patents SARS associated spike protein on CoV and pursues patent US 7,491,489 (https://patents.google.com/patent/US7491489B2/) 2005 DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. 2008 Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill: https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104 2009 Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID) 2010 Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID) Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents. August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 (https://patents.google.com/patent/US9447164B2/) which attracted the investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation Grant #0434507. While the application claims priority to August 2010, the application didn’t get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims. https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf 2011 Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology. Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID) 2012 MERS isolated in Egypt, Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID) 2013 Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID) 2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435 Fauci/COVID-19 Dossier 2015 Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella. (https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html) 2016 NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. (https://patents.google.com/patent/WO2018081318A1/en) Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013(https://patents.google.com/patent/AU2014231357A1) 2017 August – Sanofi buys Protein Science Corp with considerable SARS patent holdings 2018 June – Sanofi buys Ablynx with considerable SARS patent holdings 2019 March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create-affordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in October 2019.
Why the fuck did he just NOW make this video? We've been spamming this for years (March 2020) getting called QAnon conspiracy theorists. What is Ralph Baric's connections to UNC Chapel Hill? 1986-1990 NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant Coronavirus” Filed 2002 and issued 2007 (https://patents.google.com/patent/US7279327B2/ru) The paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf 1990 Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain. (https://patents.google.com/patent/US6372224B1/) 1990s Work focused on CoV association with cardiomyopathy (see above) Early reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf 2001 National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI 2002 Asia CoV SARS outbreak 2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus. Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges Scientific Advisory Board (served through 2010). April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319 July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2 Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants: A128785, A148436, and A1053822. 2004 January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. (https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706) At this conference, the term “The New Normal” was introduced by Merck... FAUCI AND BARIC start making money!!! SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection. National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million. November 22, 2004 University of Hong Kong patents SARS associated spike protein on CoV and pursues patent US 7,491,489 (https://patents.google.com/patent/US7491489B2/) 2005 DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. 2008 Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill: https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104 2009 Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID) 2010 Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID) Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents. August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 (https://patents.google.com/patent/US9447164B2/) which attracted the investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation Grant #0434507. While the application claims priority to August 2010, the application didn’t get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims. https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf 2011 Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology. Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID) 2012 MERS isolated in Egypt, Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID) 2013 Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID) 2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435 Fauci/COVID-19 Dossier 2015 Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella. (https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html) 2016 NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. (https://patents.google.com/patent/WO2018081318A1/en) Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013(https://patents.google.com/patent/AU2014231357A1) 2017 August – Sanofi buys Protein Science Corp with considerable SARS patent holdings 2018 June – Sanofi buys Ablynx with considerable SARS patent holdings 2019 March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create-affordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in October 2019.
Why the fuck did he just NOW make this video? We've been spamming this for years (March 2020) getting called QAnon conspiracy theorists. What is Ralph Baric's connections to UNC Chapel Hill? 1986-1990 NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant Coronavirus” Filed 2002 and issued 2007 (https://patents.google.com/patent/US7279327B2/ru) The paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf 1990 Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain. (https://patents.google.com/patent/US6372224B1/) 1990s Work focused on CoV association with cardiomyopathy (see above) Early reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf 2001 National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI 2002 Asia CoV SARS outbreak 2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus. Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges Scientific Advisory Board (served through 2010). April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319 July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2 Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants: A128785, A148436, and A1053822. 2004 January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. (https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706) At this conference, the term “The New Normal” was introduced by Merck... FAUCI AND BARIC start making money!!! SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection. National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million. November 22, 2004 University of Hong Kong patents SARS associated spike protein on CoV and pursues patent US 7,491,489 (https://patents.google.com/patent/US7491489B2/) 2005 DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf 2008 Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill: https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104 2009 Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID) 2010 Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID) Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents. August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 (https://patents.google.com/patent/US9447164B2/) which attracted the investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation Grant #0434507. While the application claims priority to August 2010, the application didn’t get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims. https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf 2011 Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology. Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID) 2012 MERS isolated in Egypt, Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID) 2013 Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID) 2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435 Fauci/COVID-19 Dossier 2015 Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella. (https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html) 2016 NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. (https://patents.google.com/patent/WO2018081318A1/en) Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013(https://patents.google.com/patent/AU2014231357A1) 2017 August – Sanofi buys Protein Science Corp with considerable SARS patent holdings 2018 June – Sanofi buys Ablynx with considerable SARS patent holdings 2019 March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create-affordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in October 2019.
Why the fuck did he just NOW make this video? We've been spamming this for years (March 2020) getting called QAnon conspiracy theorists. What is Ralph Baric's connections to UNC Chapel Hill? 1986-1990 NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant Coronavirus” Filed 2002 and issued 2007 (https://patents.google.com/patent/US7279327B2/ru) The paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf 1990 Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain. (https://patents.google.com/patent/US6372224B1/) 1990s Work focused on CoV association with cardiomyopathy (see above) Early reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf 2001 National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI 2002 Asia CoV SARS outbreak 2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus. Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges Scientific Advisory Board (served through 2010). April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319 July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2 Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants: A128785, A148436, and A1053822. 2004 January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. (https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706) At this conference, the term “The New Normal” was introduced by Merck... FAUCI AND BARIC start making money!!! SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection. National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million. November 22, 2004 University of Hong Kong patents SARS associated spike protein on CoV and pursues patent US 7,491,489 (https://patents.google.com/patent/US7491489B2/) 2005 DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf 2008 Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill: https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104 2009 Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID) 2010 Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID) Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents. August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 (https://patents.google.com/patent/US9447164B2/) which attracted the investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation Grant #0434507. While the application claims priority to August 2010, the application didn’t get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims. https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf 2011 Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology. Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID) 2012 MERS isolated in Egypt, Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID) 2013 Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID) 2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435 Fauci/COVID-19 Dossier 2015 Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella. (https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html) 2016 NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. (https://patents.google.com/patent/WO2018081318A1/en) Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013(https://patents.google.com/patent/AU2014231357A1) 2017 August – Sanofi buys Protein Science Corp with considerable SARS patent holdings 2018 June – Sanofi buys Ablynx with considerable SARS patent holdings 2019 March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create-affordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in October 2019.
ig
👀on Klaus Schwab supervillain chimeric cyborg agenda. NIAID Grant AI23946 leading to US Patent#US7279327B2 "Methods for Producing Recombinant Coronavirus" https://patents.google.com/patent/US7279327B2
April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319 July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent US7151163B2 and US7618802B2 "Antiviral agents for the treatment, control and prevention of infections by coronaviruses" https://patents.google.com/patent/US7151163B2/en "Compositions of coronaviruses with a recombination-resistant genome" https://patents.google.com/patent/US7618802B2
May 14, 2007 US Patent #US7776521B1 "Coronavirus isolated from humans"
June 28, 2007 #US7776521B1 Assigned to THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
2012 MERS isolated in Egypt
2016 NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. (https://patents.google.com/patent/WO2018081318A1/en) Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS CoV-2 according to Moderna’s report.
In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013(https://patents.google.com/patent/AU2014231357A1) 2017 August – Sanofi buys Protein Science Corp with considerable SARS patent holdings 2018 June – Sanofi buys Ablynx with considerable SARS patent holdings 2019 March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create-affordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in October 2019.
https://www.centerforhealthsecurity.org/event201/
1986-1990 NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant Coronavirus” Filed 2002 and issued 2007 (https://patents.google.com/patent/US7279327B2/ru) The paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf 1990 Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain. (https://patents.google.com/patent/US6372224B1/) 1990s Work focused on CoV association with cardiomyopathy (see above) Early reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf 2001 National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI 2002 Asia CoV SARS outbreak 2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus. Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges Scientific Advisory Board (served through 2010). April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319 July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2 Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants: A128785, A148436, and A1053822. 2004 January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. (https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706) At this conference, the term “The New Normal” was introduced by Merck... FAUCI AND BARIC start making money!!! SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection. National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus